Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Transplantation for Multiple Myeloma
NCT00177047Phase 3Completed
- Sponsor
- Masonic Cancer Center
- Start
- Apr 2004
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of melphalan in multiple myeloma (MM), sponsored by Masonic Cancer Center. Primary endpoint: Complete Response at 12 months. Started Apr 2004; status: completed.
02
Drugs
melphalan
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00177047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00177047.